m6A-centered Drug Response Information
General Information of the Drug (ID: M6APDG00097)
Name |
Thymoquinone
|
||||
---|---|---|---|---|---|
Synonyms |
490-91-5; Thymoquinon; p-Cymene-2,5-dione; 2-Isopropyl-5-methyl-1,4-benzoquinone; 2,5-CYCLOHEXADIENE-1,4-DIONE, 2-METHYL-5-(1-METHYLETHYL)-; 2-Isopropyl-5-methyl-p-benzoquinone; 2-Isopropyl-5-methylbenzoquinone; Polythymoquinone; 5-Isopropyl-2-methyl-1,4-benzoquinone; 2-Isopropyl-5-methylbenzo-1,4-quinone; p-Mentha-3,6-diene-2,5-dione; NSC 2228; 2-Isopropyl-5-methylcyclohexa-2,5-diene-1,4-dione; 2-Methyl-5-isopropyl-p-benzoquinone; 2-methyl-5-propan-2-ylcyclohexa-2,5-diene-1,4-dione; NSC2228; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione; UNII-O60IE26NUF; 2-Methyl-5-isopropyl-1,4-benzoquinone; O60IE26NUF; 2,5-Cyclohexadiene-1,4-dione, 5-isopropyl-2-methyl-; NSC-2228; 5-Isopropyl-2-methyl-p-benzoquinone; MFCD00001602; 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione; p-Mentha-3,6-diene-2,5-dione (8CI); 5-Isopropyl-2-methyl-2,5-Cyclohexadiene-1,4-dione; CCRIS 7152; EINECS 207-721-1; 2-methyl-5-(methylethyl)cyclohexa-2,5-diene-1,4-dione; BRN 1939047; thymolquinone; Thymoil; AI3-17758; 4hco; p-Mentha-3,5-dione; Spectrum_001237; SpecPlus_000457; Thymoquinone, >=98%; Spectrum2_000700; Spectrum3_001345; Spectrum4_001895; Spectrum5_000550; BSPBio_003129; KBioGR_002455; KBioSS_001717; DivK1c_006553; SCHEMBL542535; SPBio_000859; CHEMBL1672002; DTXSID9060079; KBio1_001497; KBio2_001717; KBio2_004285; KBio2_006853; KBio3_002349; Thymoquinone, analytical standard; CHEBI:113532; 2-Methyl-5-iso-propylbenzoquinone; BDBM166686; ZINC164367; BCP16946; HY-D0803; WLN: L6V DVJ B1 EY1&1; 2,4-dione, 5-isopropyl-2-methyl-; ANW-41600; CCG-40027; s4761; SBB008296; AKOS003368628; MCULE-9899033250; NCGC00178250-01; NCGC00178250-05; 73940-92-8; AK101679; AS-11327; 2-Isopropyl-5-methylbenzo-1,4-quinone #; 2,4-dione, 2-methyl-5-(1-methylethyl)-; CS-0012226; FT-0612708; ST45023960; K-9199; SR-05000002192; Q7799650; SR-05000002192-2; W-202869; BRD-K97566842-001-03-5; Thymoquinone; 2-isopropyl-5-methylbenzo-1,4-quinone; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione (F8); 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione, 9CI
Click to Show/Hide
|
||||
Status |
Phase 2/3
|
||||
Structure |
|
||||
Formula |
C10H12O2
|
||||
InChI |
1S/C10H12O2/c1-6(2)8-5-9(11)7(3)4-10(8)12/h4-6H,1-3H3
|
||||
InChIKey |
KEQHJBNSCLWCAE-UHFFFAOYSA-N
|
||||
PubChem CID | |||||
TTD Drug ID |
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Apoptosis regulator BAX (BAX)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response | ||||
Response Summary | Apoptosis regulator BAX (BAX) is a therapeutic target for Thymoquinone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Thymoquinone through regulating the expression of Apoptosis regulator BAX (BAX). | [1], [2] | ||
Apoptosis regulator Bcl-2 (BCL-2)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response | ||||
Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Thymoquinone. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Thymoquinone through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [3], [4] | ||
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response | ||||
Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Thymoquinone. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Thymoquinone through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [4], [5] | ||
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response | ||||
Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Thymoquinone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Thymoquinone through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [4], [6] | ||
RNA demethylase ALKBH5 (ALKBH5)
In total 1 mechanisms lead to this potential drug response | ||||
Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Thymoquinone. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Thymoquinone through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [4], [7] | ||
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response | ||||
Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Thymoquinone. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Thymoquinone through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [4], [6] | ||
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response | ||||
Response Summary | Apoptosis regulator Bcl-2 (BCL-2) is a therapeutic target for Thymoquinone. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Thymoquinone through regulating the expression of Apoptosis regulator Bcl-2 (BCL-2). | [4], [8] | ||
Cellular tumor antigen p53 (TP53)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response | ||||
Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for Thymoquinone. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Thymoquinone through regulating the expression of Cellular tumor antigen p53 (TP53). | [9], [10] | ||
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response | ||||
Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for Thymoquinone. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Thymoquinone through regulating the expression of Cellular tumor antigen p53 (TP53). | [10], [11] | ||
Methyltransferase-like 16 (METTL16)
In total 1 mechanisms lead to this potential drug response | ||||
Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for Thymoquinone. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of Thymoquinone through regulating the expression of Cellular tumor antigen p53 (TP53). | [10], [12] | ||
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response | ||||
Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for Thymoquinone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Thymoquinone through regulating the expression of Cellular tumor antigen p53 (TP53). | [10], [13] | ||
RNA demethylase ALKBH5 (ALKBH5)
In total 1 mechanisms lead to this potential drug response | ||||
Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for Thymoquinone. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of Thymoquinone through regulating the expression of Cellular tumor antigen p53 (TP53). | [10], [14] | ||
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response | ||||
Response Summary | Cellular tumor antigen p53 (TP53) is a therapeutic target for Thymoquinone. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Thymoquinone through regulating the expression of Cellular tumor antigen p53 (TP53). | [10], [15] | ||
References